Navigation Links
Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/10/2013

BLUE BELL, Pa., May 10, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended March 31, 2013.

Total revenue was $1.5 million for the three months ended March 31, 2013, compared to $1.7 million for the same period in 2012. Total operating expenses were $8.1 million compared to $5.9 million. The net loss attributable to common stockholders was $8.8 million, or $0.06 per share, compared to $8.3 million, or $0.06 per share.

Revenue The decrease in revenue for the comparable periods was primarily due to timing of work performed under the company's contract with the National Institute of Allergy and Infectious Diseases (NIAID). This contract revenue amounted to $1.0 million versus $1.5 million, respectively. This NIAID contract, which provides up to $25.3 million of funding over seven years, is facilitating Inovio's development of a universal, preventive HIV DNA vaccine, PENNVAX®-GP.

Operating Expenses Research and development expenses for Q1 2013 were $5.1 million compared to $4.0 million for Q1 2012. This increase was primarily due to $788,000 in higher clinical expenses related to our ongoing HPV-003 clinical trial. General and administrative expenses were $3.0 million versus $2.5 million, respectively.

Net Loss Attributable to Common Stockholders The $590,000 increase in net loss for the comparable periods resulted primarily from an increase in operating expenses offset by a lower (non-cash) change in fair value of common stock warrants, based on a required quarterly mark to market adjustment to reflect changes in the Company's stock price.

Capital Resources As of March 31, 2013, cash and cash equivalents plus short-term investments were $28.2 million compared with $13.8 million as of December 31, 2012.

On March 7, 2013, we closed an underwritten offering of 27,377,266 shares of our common stock and warrants to purchase an agg
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
2. Inovio Pharmaceuticals to Present at Noble Financial 8th Annual Equity Conference
3. Inovios Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science
4. Inovio Pharmaceuticals to Present at Noble Financial Life Sciences Conference
5. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
6. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
9. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
10. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
11. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 Research and Markets ... Genomics and Proteomics Analytical Instruments Market 2014-2018" report ... Genomics is the study of the ... of the structure and functions of proteomes or sets ... and technology. Genomics involves the mapping of genes and ...
(Date:7/24/2014)... 24, 2014  CorMedix Inc. (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... notice on July 18, 2014 from the NYSE ... the CorMedix plan to regain compliance with continued ... the NYSE-MKT is continuing the Company,s listing and ...
(Date:7/24/2014)... 24, 2014  Neogen Corporation (Nasdaq: NEOG ... its potential revenue from new rodenticide research are premature. ... analysts on July 22, 2014, Neogen,s CEO commented about ... research. "It was my intent Tuesday at ... of a new type of rodenticide, but certainly not ...
(Date:7/24/2014)... Toronto, Canada (PRWEB) July 24, 2014 ... for Optimizing Dose Escalation in First in Human Studies” ... to make better go/no-go decisions. , With increasing R&D ... market, pharmaceutical companies need to maximize the knowledge collected ... go/no-go decisions and improve success in late stage development. ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Neogen comments on SenesTech 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... , SAN DIEGO, June 8 , , ... 51 speakers and panelists discussing life sciences and the business relationships ... WHAT: , CALAsia is an international 2-day forum that ... and the Asia Pacific region to identify, explore, and further trans-Pacific ...
... on Testing OVAR Effectiveness , , PITTSBURGH, June ... ), manufacturers of noninvasive medical evaluation equipment used ... disorders, said today that the University of Michigan ... has purchased and installed its I-Portal(R) NOTC (Neuro-Otologic Test ...
... 8 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA ... that it,begins the production of a vaccine against influenza A (H1N1) ... to the company on June 8, 2009. , ... ,In,the midst of a global outbreak and transmission of H1N1, our ...
Cached Biology Technology:BIOCOM's Inaugural CALAsia Forum 'Bridging the Pacific' 2University of Michigan Installs Neuro Kinetics' I-Portal(R) NOTC System 2University of Michigan Installs Neuro Kinetics' I-Portal(R) NOTC System 3Sinovac Begins the Production of Influenza A (H1N1) Vaccine 2Sinovac Begins the Production of Influenza A (H1N1) Vaccine 3
(Date:7/24/2014)... is available in German . ... 300 million asthma sufferers worldwide, a further 600 million ... of the global population contending with allergic rhinitis (allergic ... also affect other organs and parts of the body ... intestine (in the form of inflammatory bowel diseases such ...
(Date:7/24/2014)... is available in German . ... recognize and respond to threats to health, and to ... understanding of the mechanism underlying immunologic memory, however, has ... converged to support the hypothesis that the persistence of ... with stem-cell-like potential. Until now, there was no conclusive ...
(Date:7/23/2014)... of identical twins has found that early reading skill ... the journal Child Development , was conducted by ... London. , "Since reading is an ability that can ... according to Stuart J. Ritchie, research fellow in psychology ... "Early remediation of reading problems might aid not only ...
Breaking Biology News(10 mins):New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3Experiments prove 'stemness' of individual immune memory cells 2Experiments prove 'stemness' of individual immune memory cells 3Stronger early reading skills predict higher intelligence later 2
... (LOS ANGELES, CA) -- The Disability Rights Legal Center ... civil rights of people with disabilities, has recognized Ossur, ... non-invasive orthopaedic products and services, with the Charles D. ... of Prosthetics for Ossur Americas, accepted the award on ...
... soft drink is 20 ounces and contains 17 teaspoons of ... fruit drinks are more erosive than hydrochloric or sulfuric acidwhich ... acids found in soda and citrus juice promote tooth erosion, ... the enamel. Once tooth enamel is lost, it,s gone forever. ...
... INDIANAPOLIS Although its been over a decade since ... the blood repairing and replacing the cells that line ... EPCs are now being studied as biomarkers to assess ... agents for vascular regeneration. Researchers from ...
Cached Biology News:Disability Rights Legal Center honors Ossur 2Drink brewed tea to avoid tooth erosion 2Understanding how oxidative stress impairs endothelial progenitor cell function 2
... high experimental throughput, minimum input of ... 4 up to 16 culture vessels ... users with proven fermentation results when ... fungi or any other microbial application. ...
... Experion system, 100-120 and 220-240 V, is ... steps of gel-based electrophoresis, including some data ... is used for protein analysis (it does ... RNA analysis). The system includes the electrophoresis ...
... in the submicron range are part of ... and control of particle size is important ... can reliably detect the component populations in ... Particle Size Analyzer uses Photon Correlation Spectroscopy ...
... Binding: High, 400 ng IgG/cm 2 ... Interaction: Hydrophobic/Ionic , Performance Certified: Well-to-Well, CV ... Maximum Well Volume: 360 µl , Packaging: ... ,Features, Special optically clear polystyrene formulation , ...
Biology Products: